Russia permanently registers Favipiravir for COVID-19 treatment
Publish- October 29, 2020, 03:39 PM
UNB NEWS - UNB NEWS
Favipiravir, a drug used to treat COVID-19, has received permanent registration in Russia, Russian Deputy Health Minister Viktor Fisenko said on Thursday, reports TASS.
No serious side effects of favipiravir recorded in Russia, Healthcare Ministry says.
"Following a sped-up procedure, we have greenlit circulation of prevention drugs (vaccines), antiviral therapy drugs - Favipiravir, Remdesivir, and a drug used to mitigate a cytokine storm - Levilimab," he said, adding that Favipiravir has received a permanent registration certificate.
Earlier, the Russian Federal Service for Surveillance in Healthcare informed that Russia had registered three drugs based on Favipiravir: Avifavir, Areplivir and Coronavirus.
The watchdog has not received any complaints of non-specific motor disorders during the use of the drugs.